2018 

Prasad V. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Intern Med. Published online August 13, 2018. doi:10.1001/jamainternmed.2018.3695

Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. European Journal of Cancer. 2018;101:244-250.

Nishikawa G, Luo J, Prasad V. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer. 2018;101:143-151.

Prasad V.,Cifu A. The Necessity of Sham Controls. The American Journal of Medicine.2018.doi: https://doi.org/10.1016/j.amjmed.2018.07.030

Prasad V., Lindner S.Why is Research in Early-Stage Cancer Research so Low? Journal of Cancer Policy. 2018.

Haslam A, Prasad V. Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose How Do We Know That? Circulation: Cardiovascular Quality and Outcomes. 2018; 11e004886. 

Gill J, Obley AJ, Prasad V. Direct-to-Consumer Genetic Testing The Implications of the US FDA’s First Marketing Authorization for BRCA Mutation Testing. JAMA. 2018;319(23):2377–2378. 

Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. The Lancet Haematology.

Deloughery EP, Prasad V. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of General Internal Medicine. 2018.

Chen EY-s, Joshi SK, Prasad V. FDA acceptance of surrogate endpoints in later lines of therapy. Journal of Clinical Oncology 2018;36:6517.

Tao DL, Gay ND, Prasad V. Statistical significance of bevacizumab trials when considering the portfolio of all studies. Journal of Clinical Oncology 2018;36:6551.

Gyawali B, Prasad V. Pemetrexed in Nonsquamous Non–Small-Cell Lung Cancer The Billion Dollar Subgroup Analysis. JAMA Oncol. 2018;4(1):17–18

Prasad V. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15(1):11-12.

Lu E, Shatzel J, Shin F, Prasad V. What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. Semin Oncol. 2017;44.

Prasad V, McCabe C, Mailankody S. Low drug approval standards. NRCO

Marquart J, Chen EY, Prasad V. Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology. JAMA Oncology. 2018.

Prasad V, Kaestner V, Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018;4(2):157-158.

Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Annals of Oncology. 2018:mdy116-mdy116.

Gerrity MS, Prasad V, Obley AJ. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Intern Med. 2018;178(6):743–744. doi:10.1001/jamainternmed.2018.0869

Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor t-cell immunotherapy. JAMA Oncology. 2018.

DeLoughery EP, Prasad V. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation. Ann Oncol. 2018;29(3):527-529.

Kaestner V, Edmiston JB, Prasad V. The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ open. 2018;6(1):E57-e62.

Prasad V. Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. Annals of Oncology. 2018;29(2):298-300.

Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG. Reversal of warfarin era thinking. Journal of internal medicine. 2018;283(4):408-410.

Chen EY, Prasad V. Crossover is not associated with faster trial accrual. Ann Oncol. 2018;29(3):776-777.

Hayes MJ, Kaestner V, Mailankody S, Prasad V. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ open. 2018;6(1):E31-e38.

Prasad V. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? JAMA pediatrics. 2018;172(2):123-125.

Wagner J, Marquart J, Ruby J, et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ. 2018;360.

Luo J, Prasad V. The US Food and Drug Administration’s use of pathologic complete response as regulatory endpoint: Did it pay off? Journal of Cancer Policy. 2018;16:49-51.

Prasad V. Cost-effectiveness of nusinersen for spinal muscular atrophy—reply. JAMA pediatrics. 2018.

Michael J. Hayes and Vinay Prasad, “Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings,” Hastings Center Report 48, no. 2 (2018): 10–13. 10.1002/hast.833

 

2017

Prasad V. Do cancer drugs improve survival or quality of life? BMJ. 2017;359.

Prasad V, Kaestner V, Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018;4(2):157-158.

Tayapongsak Duggan K, De Jesus K, Kemp R, Prasad V. Use of word “unprecedented” in the media coverage of cancer drugs: Do “unprecedented” drugs live up to the hype? Journal of Cancer Policy. 2017;14:16-20.

Prasad V. Unanticipated outcomes: A medical memoir—a book review. JAMA Internal Medicine. 2018;178(1):11-12.

Prasad V. Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? J Gen Intern Med. 2018;33(1):3-5.

Tao DL, Boothby A, McLouth J, Prasad V. Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Intern Med. 2017;177(3):425–427.

Kaestner V, Prasad V. The availability of jobs in the biopharmaceutical industry is 45-fold greater for hematology oncology than medical specialties. Blood Cancer Journal. 2017;7:e619.

Kaestner V, Prasad V. Financial conflicts of interest among editorialists in high-impact journals. Blood Cancer Journal. 2017;7:e611.

Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology. 2017.

Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Medicine. 2017;15(1):134.

Dreicer JJ, Mailankody S, Fahkrejahani F, Prasad V. Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer Journal. 2017;7(12):645.

Mailankody S, Prasad V. Pharmaceutical Marketing for Rare Diseases Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. JAMA. 2017;317(24):2479–2480.

Goldstein, D. A., Bilal, U. and Prasad, V. (2017), Pembrolizumab as first‐line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?. Cancer, 123: 3872-3874. 

Lammers A, Edmiston J, Kaestner V, Prasad V. Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings. Mayo Clin Proc. 2017;92(7):1164-1166.

Prasad V, De Jesus K, Mailankody S. A further strategy to combat the high price of anticancer drugs. Nat Rev Clin Oncol. 2017.

Gyawali B, Prasad V. Combining drugs and extending treatment - a PFS end point is not sufficient. Nat Rev Clin Oncol. 2017;14(9):521-522.

Kaestner V, Brown A, Tao D, Prasad V. Conflicts of interest in Twitter. The Lancet Haematology. 2017;4(9):e408-e409.

Prasad V. How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. The American Journal of Medicine. 2017;130(7):769-770.

Gyawali B, Prasad V. Drugs that lack single-agent activity: are they worth pursuing in combination? Nat Rev Clin Oncol. 2017;14(4):193-194.

De Jesus-Morales K, Prasad V. Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. Hastings Center Report. 2017;47(3):9-14.

Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. 2017.

Gyawali B, Prasad V. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2017.

Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381-390.

 

2016

Prasad V, Oseran A. Multiple Comparisons in Variation of Care Research. University of Ottawa Journal of Medicine. 2017;7(1).

Mailankody S, Prasad V. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncol. 2017;3(7):889-890.

Lammers A, DeLoughery T, Prasad V. Heparin-induced thrombocytopenia: a tremendous opportunity for randomization. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2017;28(3):272-274.

Vandross A, Prasad V, Mailankody S. ASCO Plenary Sessions: impact, legacy, future. Semin Oncol. 2016;43(3):321-326.

Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? European Journal of Heart Failure. 2016;18(2):128-132.

Prasad V, Wang R, Afifi S, Mailankody S. The rising price of cancer drugs—a new old problem? JAMA Oncology. 2017;3(2):277-278.

Prasad V, Oseran A, Fakhrejahani F. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? European Journal of Cancer. 2016;54:159-162.

Prasad V, Mailankody S. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clin Proc. 2016;91(6):707-712.

Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”—and what we can do about it. BMJ. 2016;352.

Prasad V, Kumar H, Mailankody S. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. Journal of Global Oncology. 2016;2(1):1-3.

Abola MV, Prasad V. Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clin Proc. 2016;91(11):1668-1670.

Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leukemia research. 2016;48:73-77.

Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81-e86.

Prasad V. Precision medicine in diffuse large B-cell lymphoma: Hype or hope? Eur J Cancer. 2016;68:22-26.

Prasad V. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? Medical hypotheses. 2016;93:71-73.

Prasad V. How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(3):365-366.

Prasad V, Rajkumar SV. Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward. Blood Cancer Journal. 2016;6(11):e489.

Prasad V. Translation failure and medical reversal: Two sides to the same coin. Eur J Cancer. 2016;52:197-200.

Parikh RB, Prasad V. Blood-based screening for colon cancer: A disruptive innovation or simply a disruption? JAMA. 2016;315(23):2519-2520.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist. 2016;21(3):261-268.

Prasad V. Perspective: The precision-oncology illusion. Nature. 2016;537:S63.

Mailankody S, Prasad V. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. Jama. 2016;316(3):271-272.

Mailankody S, Prasad V. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist. 2016;21(9):1031-1032.

Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clinic Proceedings. 2016;91(6):713-725.

Gyawali B, Prasad V. Same Data; Different Interpretations. Journal of Clinical Oncology. 2016;34(31):3729-3732.

Dhruva SS, Prasad V. Application of medicare’s new technology add-on payment program for blinatumomab. JAMA Oncology. 2016;2(2):165-166.

Cifu A, Prasad V. Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? J Gen Intern Med. 2016;31(11):1367-1368.

Boothby A, Wang R, Cetnar J, Prasad V. Effect of the American Society of Clinical Oncology’s conflict of interest policy on information overload. JAMA Oncology. 2016;2(12):1653-1654.

Bien J, Prasad V. Future jobs of FDA’s haematology-oncology reviewers. BMJ. 2016;354.

Beer TM, Prasad V. Taking care of our friends and neighbors: DeVita’s the death of cancer and the challenge of letting go. JAMA Oncology. 2017;3(1):16-17.

Abola MV, Prasad V. Characteristics and conflicts of public speakers at meetings of the oncologic drugs advisory committee to the us food and drug administration. JAMA Internal Medicine. 2016;176(3):389-391.

Abola MV, Prasad V. The use of superlatives in cancer research. JAMA Oncology. 2016;2(1):139-141.

 

2015

Tilak G, Prasad V, Jena AB. Authorship Inflation in Medical Publications. Inquiry : a journal of medical care organization, provision and financing. 2015;52.

Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6(18):16766-16773.

Prasad V, Vandross A. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc. 2015;90(12):1639-1649.

Prasad V, Oseran A. Do we need randomised trials for rare cancers? Eur J Cancer. 2015;51(11):1355-1357.

Prasad V, Mailankody S. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015;126(15):1860-1861.

Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175.

Prasad V, Goldstein JA. Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. Eur J Cancer. 2015;51(17):2718-2723.

Prasad V, Diener-West M. Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2015;187(9):E276-278.

Prasad V, Bilal U. The role of censoring on progression free survival: oncologist discretion advised. Eur J Cancer. 2015;51.

Prasad V, Berger VW. Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc. 2015;90(9):1171-1175.

Prasad V. But how many people died? Health outcomes in perspective. Cleveland Clinic journal of medicine. 2015;82(3):146-150.

Prasad V. Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. American family physician. 2015;92(8):678-680.

Prasad V. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? Eur J Cancer. 2015;51(16):2272-2274.

Prasad V. Use of the Word “Cure” in the Oncology Literature. American Journal of Hospice and Palliative Medicine®. 2014;32(5):477-483.

Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 2015;16(7):1014-1018.

Mailankody S, Prasad V. Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. The Oncologist. 2015;20(11):1344-1346.

Mailankody S, Prasad V. Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncology. 2015;1(4):539-540.

Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175.

Jena AB, Prasad V, Goldman DP, Romley J. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med. 2015;175(2):237-244.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol. 2015;1(6):787-795.

Huded C, Prasad V. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2015;15(6):379-386.

Goldstein JA, Prasad V. Disease Specific Productivity of American Cancer Hospitals. PLOS ONE. 2015;10(3):e0121233.

Cifu AS, Prasad VK. Medical Debates and Medical Reversal. Journal of General Internal Medicine. 2015;30(12):1729-1730.

Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol. 2015;16(4):364-366.

Burotto M, Prasad V. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. Cancer. 2015;121(16):2668-2670.

Rho J, Ho N, Prasad V. Roflumilast in COPD: Response. CHEST. 2015;148(1):e31-e32.

 

2014

Vaduganathan M, Prasad V. Modern drug development: which patients should come first? JAMA. 2014;312.

Selvaraj S, Borkar DS, Prasad V. Media coverage of medical journals: do the best articles make the news? PLoS One. 2014;9(1):e85355.

Rho J, Ho N, Prasad V. Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No. Chest. 2014;145(5):939-942.

Prasad V, Vandross A. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? Journal of cancer research and clinical oncology. 2014;140(4):521-524.

Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N. Can a resident's publication record predict fellowship publications? PLoS One. 2014;9(3):e90140.

Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620-1629.

Prasad V, Mailankody S. The accelerated approval of oncologic drugs: Lessons from ponatinib. JAMA. 2014;311(4):353-354.

Prasad V, Jena AB. The Peltzman effect and compensatory markers in medicine. Healthcare (Amsterdam, Netherlands). 2014;2(3):170-172.

Prasad V, Ioannidis JP. Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implementation Science. 2014;9(1):1.

Prasad V, Ho N. Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? Journal of clinical epidemiology. 2014;67(4):361-363.

Prasad V, Grady C. The Misguided Ethics of Crossover Trials. Contemporary clinical trials. 2014;37(2):167-169.

Prasad V, Goldstein JA. US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity? PLOS ONE. 2014;9(9):e107803.

Prasad V, Cifu A. Eliminating chronic kidney disease... as a diagnosis. Polskie Archiwum Medycyny Wewnetrznej. 2014;124(1-2):7-9.

Prasad V. Shameful. CMAJ : Canadian Medical Association Journal. 2014;186(6):472-472.

Prasad V. Rosiglitazone, medical reversal, and back to basics for diabetes. American family physician. 2014;90(6):368, 370.

Prasad V. STatins, primary prevention, and overall mortality. Annals of Internal Medicine. 2014;160(12):867-869.

Prasad V. The withdrawal of drugs for commercial reasons: The incomplete story of tositumomab. JAMA Internal Medicine. 2014;174(12):1887-1888.

Prasad V. It is time to stop screening for prostate cancer. JAMA Internal Medicine. 2014;174(11):1841-1842.

Prasad V. Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't? Journal of cancer research and clinical oncology. 2014;140(8):1353-1357.

Mailankody S, Prasad V. Comparative Effectiveness Questions in Oncology. New England Journal of Medicine. 2014;370(16):1478-1481.

Jena AB, Sun EC, Prasad V. Does the Declining Lethality of Gunshot Injuries Mask a Rising Epidemic of Gun Violence in the United States? Journal of General Internal Medicine. 2014;29(7):1065-1069.

Jena AB, Prasad V, Romley JA. Long-term Effects of the 2003 ACGME Resident Duty Hour Reform on Hospital Mortality. Mayo Clinic proceedings. 2014;89(7):1023-1025.

Jena AB, Prasad V. Primary care physicians' role in counseling about gun safety. American family physician. 2014;90(9):619-620.

Jena AB, DePasse JW, Prasad V. The Declining Demand for Hospital Care as a Rationale for Duty Hour Reform. Journal of General Internal Medicine. 2014;29(10):1400-1403.

Abola MV, Prasad V, Jena AB: Association between treatment toxicity and outcomes in oncology clinical trials. Ann Oncol 25:2284-9, 2014

 

2013

Shea N, Prasad V. Open Issues with Open Access Publication. The American Journal of Medicine. 2013;126(7):563-564.

Selvaraj S, Prasad V. Characteristics of cluster randomized trials: Are they living up to the randomized trial? JAMA Internal Medicine. 2013;173(4):313-315.

Prasad V, Vandross A, Toomey C, et al. A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings. 2013;88(8):790-798.

Prasad V, Rho J, Cifu A. The inferior vena cava filter: How could a medical device be so well accepted without any evidence of efficacy? JAMA Internal Medicine. 2013;173(7):493-495.

Prasad V, Jorgenson J, Ioannidis JP, Cifu A. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. Journal of clinical epidemiology. 2013;66(4):361-366.e364.

Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? Jama. 2013;309(3):241-242.

 Prasad V, Ho N. In vitro versus in vivo culture sensitivities: an unchecked assumption? Southwest Journal of Pulmonary Critical Care. 2013;6(3):125-7.

Prasad V, Cifu A. The reversal of cardiology practices: interventions that were tried in vain. Cardiovascular Diagnosis and Therapy. 2013;3(4):228-235.

Prasad V. Why resident physicians stay late. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2013;185(13):1184.

Prasad V. Persistent reservations against the premedical and medical curriculum. Perspectives on Medical Education. 2013;2(5-6):335-339.

Prasad V. Taking care of sick patients. CMAJ : Canadian Medical Association Journal. 2013;185(11):1008-1008.

Prasad V. Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews. Mayo Clinic Proceedings. 2013;88(10):1046-1050.

Prasad V. The overdiagnosis of pneumonia. Cleveland Clinic journal of medicine. 2013;80(10):616-618.

Prasad V. Double-crossed: why crossover in clinical trials may be distorting medical science. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(5):625-627.

Kim JK, Rho J, Prasad V. Handheld ultrasounds: pocket sized, but pocket ready? Am J Med. 2013;126(10):845-846.

Kim J, Rho J, Prasad V: Evidence based practice in chronic musculoskeletal pain? Alternative and Complementary Therapies 19:49-58, 2013

Jena AB, Prasad V. Duty hour reform in a shifting medical landscape. J Gen Intern Med. 2013;28(9):1238-1240.

Ioannidis JP, Prasad V. Evaluating health system processes with randomized controlled trials. JAMA Intern Med. 2013;173(14):1279-1280.

Huded C, Rosno J, Prasad V. When research evidence is misleading. The virtual mentor : VM. 2013;15(1):29-33.

Ho N, Kim J, Prasad V. Dense breasts and legislating medicine. Cleveland Clinic journal of medicine. 2013;80(12):768-770.

Prasad V, Cifu A. A medical burden of proof: Towards a new ethic. BioSocieties. 2012;7(1):72-87.

 

2012

Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012;172(8):656-659; discussion 659.

Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N. Publication Trends Among Internal Medicine Residents and Graduates. The American Journal of Medicine. 2012;125(9):939-944.

Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med. 2012;172(12):955-958.

Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012;33(3):199-208.

Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. Jama. 2012;307(1):37-38.

Prasad V, Cheung M, Cifu A. Chest pain in the emergency department: The case against our current practice of routine noninvasive testing. Archives of Internal Medicine. 2012;172(19):1506-1509.

Prasad V. An unmeasured harm of screening. Archives of Internal Medicine. 2012;172(19):1442-1443.

Prasad V. Holiday reading: The facts are the facts. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012;184(18):2029-2030.

Prasad V. The conundrum of cost-effectiveness. Cleveland Clinic journal of medicine. 2012;79(9):610-611.

Prasad V. The apples and oranges of cost-effectiveness. Cleveland Clinic journal of medicine. 2012;79(6):377-379.

 

2011

Straus D, Prasad V, Munoz L. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arquivos de neuro-psiquiatria. 2011;69(6):981-987.

Prasad V, Thistlethwaite W, Dale W. Effect of clinical vignettes on senior medical students' opinions of climate change. Southern medical journal. 2011;104(6):401-404.

Prasad V, Gall V, Cifu A. The frequency of medical reversal. Archives of Internal Medicine. 2011;171(18):1675-1676.

Prasad V, Cifu A. Medical Reversal: Why We Must Raise the Bar Before Adopting New Technologies. The Yale Journal of Biology and Medicine. 2011;84(4):471-478.

Prasad V, Bonow RO. The cardiovascular biomarker conundrum: challenges and solutions. Jama. 2011;306(19):2151-2152.

Prasad V. Perspective: Why There Must Be a Meditative Medicine. Alternative and Complementary Therapies. 2011;17(5):274-278.

Prasad V. Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. Teach Learn Med. 2011;23(4):337-341.

Ho N, Prasad V. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. Journal of clinical gastroenterology. 2011;45(4):379-380.

 

2010

Prasad V. Holiday reading: A la carte medicine. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010;182(18):2011-2012.

Prasad V. Reclaiming the morbidity and mortality conference: between Codman and Kundera. Medical humanities. 2010;36(2):108-111.

Prasad V: Language in the end. Explaining the death of a loved one. J Gen Intern Med 25:884-5, 2010

Prasad V. Perspective: beyond storytelling in medicine: an encounter-based curriculum. Academic medicine : journal of the Association of American Medical Colleges. 2010;85(5):794-798.

Prasad V. Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Medical hypotheses. 2010;75(6):639-641.

 

2009

Prasad, V. (2009). Toward a Meaningful Alternative Medicine. The Hastings Center Report, 39(5), 16-18.